A detailed history of D.A. Davidson & Co. transactions in A Tyr Pharma Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 29,000 shares of LIFE stock, worth $53,940. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,000
Previous 27,850 4.13%
Holding current value
$53,940
Previous $43,000 23.26%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.51 - $2.24 $1,736 - $2,576
1,150 Added 4.13%
29,000 $53,000
Q2 2024

Jul 31, 2024

BUY
$0.0 - $2.07 $0 - $3,104
1,500 Added 5.69%
27,850 $43,000
Q1 2024

May 13, 2024

BUY
$1.42 - $2.02 $19,312 - $27,472
13,600 Added 106.67%
26,350 $51,000
Q4 2023

Feb 09, 2024

SELL
$1.11 - $1.51 $11,100 - $15,100
-10,000 Reduced 43.96%
12,750 $17,000
Q2 2023

Aug 10, 2023

BUY
$1.72 - $2.57 $18,490 - $27,627
10,750 Added 89.58%
22,750 $49,000
Q1 2023

Apr 25, 2023

SELL
$1.88 - $2.5 $1,504 - $2,000
-800 Reduced 6.25%
12,000 $25,000
Q4 2022

Feb 03, 2023

BUY
$2.02 - $2.49 $2,020 - $2,490
1,000 Added 8.47%
12,800 $28,000
Q3 2022

Nov 07, 2022

BUY
$2.79 - $4.15 $2,790 - $4,150
1,000 Added 9.26%
11,800 $35,000
Q2 2022

Jul 28, 2022

BUY
$2.63 - $5.61 $28,404 - $60,588
10,800 New
10,800 $31,000

Others Institutions Holding LIFE

About aTYR PHARMA INC


  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $53.2M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.